AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10963500 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-1 levels after 6 months (T6)
Number of subjects: 57
Study 10963500 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 57
Study 8784764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N = 17)
Number of subjects: 28
Study 8784764 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 11)
Number of subjects: 28
Study 1338083 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 1338083 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 2580171 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally (acute and fasting)
Number of subjects: 9
Study 2580171 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally (with concomitant food intake)
Number of subjects: 9
Study 2580171 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally (without concomitant food intake)
Number of subjects: 9
Study 2580171 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day for 4-5 weeks (chronic treatment)
Number of subjects: 9
Study 2580171 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg (twice daily)
Number of subjects: 9
Study 31907076 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi-Qi-Qing-Jie formula (YQF) combined with prednisolone and cyclophosphamide if necessary
Number of subjects: 60
Study 31907076 — intervention group
Group type: COMPARATOR
Intervention: Placebo-YQF combined with prednisolone and cyclophosphamide if necessary
Number of subjects: 60
Study 30572928 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (3-month clinically supervised exercise programme)
Number of subjects: 40
Study 30572928 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 40
Study 26400628 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal treatment + oral antifungal
Number of subjects: 45
Study 26400628 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal treatment + ICAMB + oral antifungal
Number of subjects: 45
Study 26400628 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal treatment + drainage of hypopyon + ICAMB + oral antifungal
Number of subjects: 45
Study 24902040 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS delivered by experts only
Number of subjects: 832
Study 24902040 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS delivered by experts and peers
Number of subjects: 832
Study 24902040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to any intervention)
Number of subjects: 832
Study 22341106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FSG)
Number of subjects: 77447
Study 22341106 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy instead of FSG
Number of subjects: 77447
Study 21162931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral midazolam (Group I)
Number of subjects: 48
Study 21162931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group II)
Number of subjects: 48
Study 18519835 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) consisting of seven standardized techniques for 20 minutes.
Number of subjects: 35
Study 18519835 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (light touch applied to the same anatomic regions for 20 minutes).
Number of subjects: 35
Study 18519835 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT group
Number of subjects: 35
Study 18519835 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 35
Study 15741580 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-blinded group
Number of subjects: 100
Study 15741580 — intervention group
Group type: COMPARATOR
Intervention: BIS-unblinded group
Number of subjects: 100
Study 15741580 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-blinded group (single dose)
Number of subjects: 100
Study 15741580 — intervention group
Group type: COMPARATOR
Intervention: BIS-unblinded group (single dose)
Number of subjects: 100
Study 15741580 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-blinded group (multiple doses)
Number of subjects: 100
Study 15741580 — intervention group
Group type: COMPARATOR
Intervention: BIS-unblinded group (multiple doses)
Number of subjects: 100
Study 12915670 — intervention group
Group type: COMPARATOR
Intervention: T and placebo
Number of subjects: 23
Study 12915670 — intervention group
Group type: EXPERIMENTAL
Intervention: T and letrozole
Number of subjects: 23
Study 10566703 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.i.d. for 12 weeks
Number of subjects: 23
Study 10566703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9012256 — intervention group
Group type: EXPERIMENTAL
Intervention: lerivon (L) for 1 month
Number of subjects: 50
Study 9012256 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline for 1 month
Number of subjects: 50
Study 9012256 — intervention group
Group type: COMPARATOR
Intervention: relanium for 7 days
Number of subjects: 50
Study 1768550 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupuncture (50% of patients) for 5 min after induction of anaesthesia
Number of subjects: 45
Study 1768550 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture (50% of patients)
Number of subjects: 45
Study 7334143 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 19
Study 7334143 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital
Number of subjects: 19
Study 7334143 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 19
Study 30652944 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training and foot and ankle mobilization (FAM)
Number of subjects: 28
Study 30652944 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 28
Study 31856749 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA-two
Number of subjects: 52
Study 31856749 — intervention group
Group type: COMPARATOR
Intervention: RCA-one
Number of subjects: 52
Study 31856749 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 52
Study 27870723 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 83
Study 27870723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 25434303 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched unrelated hematopoietic cell transplantation (HCT) in first remission for patients with FLT3-ITD allelic ratio >0.8, poor day +15 marrow blast clearance, and adverse karyotypes; allogeneic HCT in high-risk AML performed in aplasia after induction chemotherapy
Number of subjects: 1179
Study 25434303 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT in aplasia
Number of subjects: 1179
Study 25434303 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT in remission
Number of subjects: 1179
Study 25434303 — intervention group
Group type: COMPARATOR
Intervention: Control arm: Sibling HCT in first complete remission for intermediate-risk or high-risk AML and matched unrelated HCT in complex karyotype AML
Number of subjects: 1179
Study 23504636 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD with PegIFN/RBV (48 weeks)
Number of subjects: 290
Study 23504636 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD without lead-in (48 weeks)
Number of subjects: 290
Study 23504636 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg BID with lead-in (48 weeks)
Number of subjects: 290
Study 23504636 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD/LI (rerandomized to 48 weeks treatment)
Number of subjects: 290
Study 23504636 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD/LI, 240 mg QD, and 240 mg BID/LI (adverse events)
Number of subjects: 290
Study 23504636 — intervention group
Group type: COMPARATOR
Intervention: Faldaprevir 240 mg BID
Number of subjects: 290
Study 21243318 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.4% vaginal extract of the Brazilian pepper tree (Schinus terebinthifolius Raddi)
Number of subjects: 277
Study 21243318 — intervention group
Group type: COMPARATOR
Intervention: 0.75% vaginal metronidazole
Number of subjects: 277
Study 19136900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40-80 mg daily)
Number of subjects: 2102
Study 19136900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 17878480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 107
Study 17878480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 17878480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (limited-stage)
Number of subjects: 107
Study 17878480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (extensive-stage)
Number of subjects: 107
Study 15306112 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement (group A)
Number of subjects: 104
Study 15306112 — intervention group
Group type: COMPARATOR
Intervention: No stent placement (group B)
Number of subjects: 104
Study 12948282 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol supplementation (50 mg/day for five to eight years)
Number of subjects: 197
Study 12948282 — intervention group
Group type: EXPERIMENTAL
Intervention: MnSOD ala/ala genotype
Number of subjects: 197
Study 10641900 — intervention group
Group type: EXPERIMENTAL
Intervention: Small hole plate haptic lenses (Chiron C10UB)
Number of subjects: 50
Study 10641900 — intervention group
Group type: COMPARATOR
Intervention: Large hole plate haptic lenses (Chiron C11UB)
Number of subjects: 50
Study 7780491 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF) 30 mg/d
Number of subjects: 20
Study 7780491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7780491 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 20
Study 2180388 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mud packs
Number of subjects: 40
Study 2180388 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hot sulphur baths
Number of subjects: 40
Study 2180388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mud packs and hot sulphur baths
Number of subjects: 40
Study 2180388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 7462801 — intervention group
Group type: EXPERIMENTAL
Intervention: cholestyramine (16g/day)
Number of subjects: 150
Study 7462801 — intervention group
Group type: EXPERIMENTAL
Intervention: clofibrate (2g/day)
Number of subjects: 150
Study 7462801 — intervention group
Group type: COMPARATOR
Intervention: both clofibrate and cholestyramine
Number of subjects: 150
Study 7462801 — intervention group
Group type: EXPERIMENTAL
Intervention: cholestyramine (8g) administered 30 min prior to test
Number of subjects: 150
Study 30713334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud-based interactive management program
Number of subjects: 79
Study 30713334 — intervention group
Group type: COMPARATOR
Intervention: Psoriasis nursing manual and regular follow-up (Control)
Number of subjects: 79
Study 28591847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (intervention group)
Number of subjects: 544
Study 28591847 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 544
Study 25630944 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP-eL (web-based e-learning platform) accessed over 4 weeks
Number of subjects: 80
Study 25630944 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP-eL (web-based e-learning platform)
Number of subjects: 80
Study 25630944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to RAP-eL)
Number of subjects: 80
Study 23837192 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 24
Study 23837192 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger decreases in MVPA throughout pregnancy
Number of subjects: 24
Study 23837192 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 24
Study 20870205 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire marking
Number of subjects: 53
Study 20870205 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue marking
Number of subjects: 53
Study 19549996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6459
Study 19549996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6459
Study 17570410 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily from postoperative days 1 to 90
Number of subjects: 50
Study 17570410 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg per day as needed
Number of subjects: 50
Study 15456678 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination intervention
Number of subjects: 417
Study 15456678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 417
Study 11199942 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (daily doses ranging from 2.5 to 17.5 mg/day for up to 6 weeks)
Number of subjects: 84
Study 11199942 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (exact dosage and duration not specified)
Number of subjects: 84
Study 11199942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (exact dosage and duration not specified)
Number of subjects: 84
Study 9698979 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of fear of negative evaluation in women
Number of subjects: 0
Study 9698979 — intervention group
Group type: COMPARATOR
Intervention: Other groups (not specified)
Number of subjects: 0
Study 8006647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (Epilim EC enteric coated 200 mg tablets twice daily)
Number of subjects: 300
Study 8006647 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (100 mg twice daily increasing to 200 mg twice daily in week 2)
Number of subjects: 300
Study 8006647 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 300
Study 8006647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 300
Study 8006647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate and carbamazepine
Number of subjects: 300
Study 29982608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 29982608 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in ACE
Number of subjects: 0
Study 29982608 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs4318 in ACE
Number of subjects: 0
Study 29982608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27451968 — intervention group
Group type: EXPERIMENTAL
Intervention: State mandatory reporting laws for healthcare-associated infections (HAIs)
Number of subjects: 244
Study 27451968 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned (control group)
Number of subjects: 244
Study 26457003 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood NH3 levels in male prisoners
Number of subjects: 101
Study 26457003 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood H2S levels in male prisoners
Number of subjects: 101
Study 26457003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behavior assessment, Self‐Rating Depression Scale (SDS), State‐Trait Anxiety Inventory (STAI)
Number of subjects: 101
Study 26457003 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 101
Study 23204544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 19
Study 23204544 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol
Number of subjects: 19
Study 23204544 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol with leakage correction
Number of subjects: 19
Study 19160404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amphotericin B
Number of subjects: 0
Study 19160404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17449993 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritable Bowel Syndrome (IBS)
Number of subjects: 37
Study 17449993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia plus Irritable Bowel Syndrome (FM+IBS)
Number of subjects: 37
Study 17449993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 17449993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand immersion
Number of subjects: 37
Study 14970005 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA mixture intake (0, 20, 30, 50, 60, 70, 90, 110, and 130 mg.kg(‐1).day(‐1))
Number of subjects: 5
Study 11961245 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus DN
Number of subjects: 12
Study 11961245 — intervention group
Group type: COMPARATOR
Intervention: Spectra LRS
Number of subjects: 12
Study 11961245 — intervention group
Group type: COMPARATOR
Intervention: MCS+
Number of subjects: 12
Study 9854277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised fitness training under bright light (2500-4000 lx) 2-3 times weekly for 8 weeks
Number of subjects: 120
Study 9854277 — intervention group
Group type: COMPARATOR
Intervention: Supervised fitness training under ordinary light (400-600 lx) 2-3 times weekly for 8 weeks
Number of subjects: 120
Study 9854277 — intervention group
Group type: COMPARATOR
Intervention: Supervised relaxation training once a week for 8 weeks (active placebo)
Number of subjects: 120
Study 9854277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised fitness training combined with bright light
Number of subjects: 120
Study 8582955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg oral administration for inhibition of puerperal lactation
Number of subjects: 0
Study 8582955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg (0.25 mg twice daily for 2 days) for suppression of established lactation
Number of subjects: 0
Study 8582955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1-2 mg weekly doses (twice weekly schedule) for hyperprolactinaemic amenorrhoea
Number of subjects: 0
Study 8582955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study 2121406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g with five-minute tourniquet inflation
Number of subjects: 24
Study 2121406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g with two-minute tourniquet inflation
Number of subjects: 24
Study 2121406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g with one-minute tourniquet inflation
Number of subjects: 24
Study 374706 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexidine mouthrinse (0.035%)
Number of subjects: 180
Study 374706 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 180
Study 31122062 — intervention group
Group type: EXPERIMENTAL
Intervention: TVBGSA model
Number of subjects: 134
Study 31122062 — intervention group
Group type: COMPARATOR
Intervention: BGSA method
Number of subjects: 134
Study 28668719 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid acting insulin analog (RAIA)
Number of subjects: 451
Study 28668719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse perceptions of RAIA dosing
Number of subjects: 451
Study 28668719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse perceptions of electronic dosing calculator and patient reminder
Number of subjects: 451
Study 28668719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia incidence
Number of subjects: 451
Study 28668719 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeliness measures and mean CBG
Number of subjects: 451
Study 25387903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 164
Study 25387903 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 164
Study 23972437 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally supported PTFE graft
Number of subjects: 334
Study 23972437 — intervention group
Group type: COMPARATOR
Intervention: Ordinary PTFE graft
Number of subjects: 334
Study 21589921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 20
Study 21589921 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study 19167693 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg
Number of subjects: 567
Study 19167693 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 150 mg
Number of subjects: 567
Study 19167693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 19167693 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 567
Study 17233679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of supervised exercise consisting of high-intensity progressive resistance training (80% of 1RM) 3 days per week, moderate-intensity aerobic training (RPE 11 to 14/20) 2 days per week, and progressive balance training 1 day per week.
Number of subjects: 38
Study 17233679 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 38
Study 17233679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of supervised exercise
Number of subjects: 38
Study 14978178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (feedback, workshops, educational materials, technical assistance, continued monitoring)
Number of subjects: 42
Study 14978178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 42
Study 14978178 — intervention group
Group type: COMPARATOR
Intervention: Feedback alone (control)
Number of subjects: 42
Study 12238431 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 10
Study 12238431 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 10
Study 12238431 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 10